Our group's research efforts aim to uncover novel cancer treatments and centre around three main themes: PROTAC, Molecular Glue Degraders, and novel E3 ligases. My earlier research in PROTAC ...
and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback